Compare ADPT & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | CASH |
|---|---|---|
| Founded | 2009 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2019 | 1996 |
| Metric | ADPT | CASH |
|---|---|---|
| Price | $14.25 | $86.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $17.78 | ★ $107.50 |
| AVG Volume (30 Days) | ★ 1.4M | 178.2K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.23% |
| EPS Growth | ★ 63.89 | 18.88 |
| EPS | N/A | ★ 1.57 |
| Revenue | $276,976,000.00 | ★ $839,894,000.00 |
| Revenue This Year | $3.98 | $7.56 |
| Revenue Next Year | $22.72 | $6.02 |
| P/E Ratio | ★ N/A | $55.43 |
| Revenue Growth | ★ 54.77 | 11.29 |
| 52 Week Low | $8.38 | $65.93 |
| 52 Week High | $20.76 | $101.26 |
| Indicator | ADPT | CASH |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 38.44 |
| Support Level | $12.22 | $87.19 |
| Resistance Level | $15.38 | $94.84 |
| Average True Range (ATR) | 0.62 | 3.18 |
| MACD | 0.02 | -1.19 |
| Stochastic Oscillator | 50.26 | 17.83 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.